The NIMBLE phase 3 trial found that cemdisiran siRNA monotherapy and combination therapy effectively treated generalized myasthenia gravis, a chronic autoimmune neuromuscular disease. Both regimens were generally well tolerated by participants, according to findings published in The Lancet.
The trial's results address a significant unmet need for more convenient treatment options in myasthenia gravis. Current therapies often require frequent intravenous infusions or daily oral medications, placing a substantial burden on patients. Cemdisiran's subcutaneous dosing schedule, administered every three months, could markedly simplify disease management.
Researchers evaluated the safety and efficacy of cemdisiran in a double-blind, randomized, placebo-controlled design. While specific numerical outcomes were not detailed in the summary, the drug demonstrated statistically significant improvements in primary endpoints compared to placebo.
If approved, this siRNA therapy would represent a novel mechanism of action for myasthenia gravis treatment, targeting complement pathway proteins. The every-three-month dosing could improve adherence and quality of life for patients who struggle with existing regimens.
Further analysis of the full dataset will be needed to understand long-term safety and durability of response.